L
Lytix Biopharma AS
OSE:LYTIX
Lytix Biopharma AS
OSE:LYTIX
Price:
10.3
NOK
-4.63%
Market Cap:
kr792.1m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
NO |
|
Mensch und Maschine Software SE
XETRA:MUM
|
DE |
|
Sichuan Meifeng Chemical Industry Co Ltd
SZSE:000731
|
CN |
|
Lacroix Group SA
PAR:LACR
|
FR |
|
Ncl Industries Ltd
NSE:NCLIND
|
IN |
|
C
|
China Finance Investment Holdings Ltd
HKEX:875
|
HK |
|
S
|
Spotify Technology SA
SWB:639
|
LU |
|
M
|
Mulpha International Bhd
KLSE:MULPHA
|
MY |
|
Croma Security Solutions Group PLC
LSE:CSSG
|
UK |
|
Natco Pharma Ltd
NSE:NATCOPHARM
|
IN |
|
Cranswick PLC
LSE:CWK
|
UK |
|
E
|
EEMS Italia SpA
MIL:EEMS
|
IT |
|
Vela Technologies PLC
LSE:VELA
|
UK |
|
Ship Healthcare Holdings Inc
TSE:3360
|
JP |
|
Ferroglobe PLC
NASDAQ:GSM
|
UK |
|
Concejo AB (publ)
STO:CNCJO B
|
SE |
|
A
|
Abans Holdings Ltd
NSE:AHL
|
IN |
|
N
|
Nex Point PCL
SET:NEX
|
TH |
|
Churchill China PLC
LSE:CHH
|
UK |
Relative Value
The Relative Value of one LYTIX stock under the Base Case scenario is hidden NOK. Compared to the current market price of 10.3 NOK, Lytix Biopharma AS is hidden .
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
LYTIX Relative Value
HIDDEN
Multiples Across Competitors
LYTIX Competitors Multiples
Lytix Biopharma AS Competitors
Lytix Biopharma AS Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| NO |
L
|
Lytix Biopharma AS
OSE:LYTIX
|
792.1m NOK | 1 328.5 | -11.1 | -10 | -9.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.3B USD | 5.9 | 86.5 | 14.4 | 20 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.5B USD | 5.1 | 24.4 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.4B USD | 5.8 | 20 | 12.5 | 15.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.6B USD | 9.5 | 29 | 21.8 | 22.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.9B USD | 5.4 | 17.3 | 12.7 | 14.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.4B AUD | 3.1 | 34.2 | 11.3 | 14.2 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
36B EUR | 10.2 | 32.8 | 35.3 | 36.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
